(Q44522300)

3 December 2017

title

Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients (English)

1 reference

3 December 2017

0 references

0 references

Teunissen CE

1

1 reference

3 December 2017

Dijkstra CD

2

1 reference

3 December 2017

Polman CH

3

1 reference

3 December 2017

Hoogervorst EL

4

1 reference

3 December 2017

von Bergmann K

5

1 reference

3 December 2017

Lütjohann D

6

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

347

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

159-162

1 reference

The pathology of primary progressive multiple sclerosis

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

Serum cholesterol, precursors and metabolites and cognitive performance in an aging population

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2803%2900667-0

7 January 2021

10.1016/S0304-3940(03)00667-0

Identifiers

DOI

1 reference

3 December 2017

1 reference